1. Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial
- Author
-
Renaud Sabatier, Frédérique Rousseau, Florence Joly, Claire Cropet, Coline Montégut, Johanna Frindte, Saverio Cinieri, Eva M. Guerra Alía, Stephan Polterauer, Hiroyuki Yoshida, Ignace Vergote, Nicoletta Colombo, Sakari Hietanen, Rémi Largillier, Ulrich Canzler, Alain Gratet, Frederik Marmé, Laure Favier, Eric Pujade-Lauraine, Isabelle Ray-Coquard, Sabatier, R, Rousseau, F, Joly, F, Cropet, C, Montegut, C, Frindte, J, Cinieri, S, Guerra Alia, E, Polterauer, S, Yoshida, H, Vergote, I, Colombo, N, Hietanen, S, Largillier, R, Canzler, U, Gratet, A, Marme, F, Favier, L, Pujade-Lauraine, E, and Ray-Coquard, I
- Subjects
Cancer Research ,Elderly ,Olaparib ,Survival ,Oncology ,Ovarian cancer ,Safety - Abstract
BACKGROUND: The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance olaparib plus bevacizumab in older patients in PAOLA-1. METHODS: Baseline clinical and molecular data, and PFS, were compared between older (aged ≥65 years) and younger patients (
- Published
- 2023
- Full Text
- View/download PDF